ABEO - Abeona Therapeutics Inc.
13.25 0.00 (0.00%)
After hours: 5:21PM EDT
| Previous Close | 13.70 |
| Open | 13.85 |
| Bid | 12.50 x 4000 |
| Ask | 13.45 x 800 |
| Day's Range | 13.00 - 14.25 |
| 52 Week Range | 7.45 - 22.75 |
| Volume | 339,651 |
| Avg. Volume | 845,509 |
| Market Cap | 635.249M |
| Beta | 1.48 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.70 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 28.98 |
- GlobeNewswire•11 hours ago
Factors of Influence in 2018, Key Indicators and Opportunity within AgroFresh Solutions, SMART SAND INC, Advantage Oil & Gas, Abeona Therapeutics, B. Riley Financial, and Audentes Therapeutics — New Research Emphasizes Economic Growth
NEW YORK, Aug. 17, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of AgroFresh ...
- Thomson Reuters StreetEvents•7 days ago
Edited Transcript of ABEO earnings conference call or presentation 10-Aug-18 2:00pm GMT
Q2 2018 Abeona Therapeutics Inc Earnings Call
- Zacks•8 days ago
Abeona Therapeutics (ABEO) Reports Q2 Loss, Lags Revenue Estimates
Abeona Therapeutics (ABEO) delivered earnings and revenue surprises of -56.25% and -54.83%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•8 days ago
Abeona Therapeutics: 2Q Earnings Snapshot
The Dallas-based company said it had a loss of 25 cents per share. The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for ...
- GlobeNewswire•8 days ago
Abeona Therapeutics Reports Second Quarter 2018 Financial Results and Business Highlights
NEW YORK and CLEVELAND, Aug. 09, 2018-- Abeona Therapeutics Inc., a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic ...
- GlobeNewswire•22 days ago
Abeona Therapeutics Announces Leadership Appointments with Max Colao as Chief Commercial Officer
Abeona Therapeutics Inc. (ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced the appointment of Max Colao as Chief Commercial Officer. Mr. Colao has more than 20 years of global pharmaceutical and biotechnology experience, having most recently served as the Senior Vice President of US Commercial Operations at Alexion Pharmaceuticals, Inc. The Company also announced Jeffrey B. Davis will be stepping down from his role as Chief Operating Officer at the end of the quarter to ensure a smooth transition. In an ongoing commitment to enhance the capabilities of its senior team, Abeona recently appointed Kristina Maximenko as Global Head of Human Resources.
- Zacks•last month
Implied Volatility Surging for Abeona Therapeutics (ABEO) Stock Options
Abeona Therapeutics (ABEO) needs investors to pay close attention to the stock based on moves in the options market lately.
- ACCESSWIRE•last month
Free Technical Reports on 22nd Century Group and Three Additional Biotech Equities
Stock Research Monitor: RGNX, RGLS, and ABEO LONDON, UK / ACCESSWIRE / July 5, 2018 / If you want a free Stock Review on XXII sign up now at www.wallstequities.com/registration . For today, WallStEquities.com ...
- Business Wire•2 months ago
Newman Ferrara LLP Announces Corporate Governance Investigation of Abeona Therapeutics Inc. – ABEO
Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of stockholders of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (ABEO) into potential breaches of fiduciary duty by the Company’s Board of Directors (the “Board”). Newman Ferrara’s investigation focuses on decisions made by the Board, without shareholder approval, the result of which significantly diminish shareholder value and do not benefit the Company.
- ACCESSWIRE•2 months ago
57% Sales Growth, Top-Notch Partners At Overlooked Gene and Cell Therapy Issue ORGS
Cell and gene therapy development hitting fever pitch globally as more products enter phase 3 and late-stage testing. Growing their sales consistently, and partnered with high-profile public clients, ORGS could be significantly undervalued with continued executiona and expansion. NEW YORK, NY / ACCESSWIRE / June 7, 2018 / The curative potential of gene and cell therapies has kept these new pharmaceutical products front and center for healthcare investors for the last 3 years.
- GlobeNewswire•2 months ago
Abeona Therapeutics Announces Upcoming Presentation at Jefferies 2018 Global Healthcare Conference
NEW YORK and CLEVELAND, June 06, 2018-- Abeona Therapeutics Inc., a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic ...
- Benzinga•2 months ago
Abeona Therapeutics Has First-Mover Potential In Rare Diseases, Seaport Says In Bullish Initiation
Abeona Therapeutics Inc (NASDAQ: ABEO ), which employs gene and cell therapy for potential rare disease treatments, has a favorable risk-reward profile, according to Seaport Global Securities. The Analyst ...
- ACCESSWIRE•2 months ago
Free Technical Research on Versartis and Three More Biotech Equities
LONDON, UK / ACCESSWIRE / June 5, 2018 / If you want a free Stock Review on VSAR sign up now at www.wallstequities.com/registration. This Tuesday, WallStEquities.com has initiated reports coverage on the following Biotechnology equities: Versartis Inc. (NASDAQ: VSAR), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), 22nd Century Group Inc. (NYSE AMER: XXII), and Abeona Therapeutics Inc. (NASDAQ: ABEO).
- Investopedia•2 months ago
9 Stocks Poised for Healthy Long-Term Gains
Stock investors looking for long-term growth plays in the health care space may seek guidance from Fidelity Fund manager Eddie Yoon, who oversees more than $35 billion in assets and leads the firm's health sector with a team of 12 investment professionals.
- GlobeNewswire•3 months ago
Abeona Therapeutics Announces Opening of Commercial Gene & Cell Therapy Manufacturing Facility in Ohio
--The Elisa Linton Center for Rare Disease Therapies to support development of advanced gene and cell therapies for treatment of serious rare diseases. --Ribbon-cutting ceremony of gene and cell therapy ...
- GlobeNewswire•3 months ago
Analysis: Positioning to Benefit within Avadel Pharmaceuticals, Abeona Therapeutics, BanColombia S.A, Aercap Holdings N.V, Kite Realty Group Trust, and Credicorp — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, May 31, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Avadel ...
- Motley Fool•3 months ago
Here's Why Abeona Therapeutics Stock Dropped 12% Today
A clinical trial update for AB-102 didn't go far enough.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of ABEO earnings conference call or presentation 14-May-18 2:00pm GMT
Q1 2018 Abeona Therapeutics Inc Earnings Call
- Simply Wall St.•3 months ago
Abeona Therapeutics Inc (NASDAQ:ABEO): Does The -41.52% Earnings Drop Reflect A Longer Term Trend?
Today I will take a look at Abeona Therapeutics Inc’s (NASDAQ:ABEO) most recent earnings update (31 March 2018) and compare these latest figures against its performance over the past fewRead More...
- Associated Press•3 months ago
Abeona Therapeutics: 1Q Earnings Snapshot
On a per-share basis, the Dallas-based company said it had a loss of 18 cents. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
- GlobeNewswire•3 months ago
Abeona Therapeutics Reports First Quarter 2018 Financial Results and Business Highlights
Investor Conference Call on Monday, May 14th at 10:00 am ET NEW YORK and CLEVELAND, May 11, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company ...
